DIRS.INFO The most relevant business & tech news

☆ AstraZeneca's Tagrisso-chemo combo results raise bar for J&J cancer drug-analysts
▼ + stars: | 2023-09-11 | by ( Maggie Fick | ) www.reuters.com time to read: +2 min

LONDON, Sept 11 (Reuters) - Data released on Monday by AstraZeneca (AZN.L) from a late-stage trial combining its blockbuster cancer drug Tagrisso with chemotherapy to treat a type of lung cancer raises the bar for Johnson & Johnson's (JNJ.N) rival treatment, analysts said. A brief summary from the Phase 3 trial, called FLAURA2, was released in May, and the detailed data was presented on Monday in Singapore at the World Conference on Lung Cancer. The FLAURA2 trial showed that when adding chemotherapy to Tagrisso, the risk of disease progression or death is reduced by 38% when compared to Tagrisso alone. "With the strong FLAURA-2 data in hand and likely included in treatment guidelines soon, the hurdle is now pretty high in our view for MARIPOSA," the UBS note read. Barclays analysts said the FLAURA2 trial data presented on Monday included doctor and patient surveys that showed a strong preference for the convenience of a single therapy compared with combinations.

Persons: Johnson, Pascal Soriot, Michel Demare, Soriot, Maggie Fick, Emelia Sithole Organizations: AstraZeneca, Lung Cancer, Barclays, UBS, Reuters, Thomson Locations: Singapore, British, MARIPOSA

☆ J&J says drug combo contains lung cancer from spreading for longer duration
▼ + stars: | 2023-09-06 | by ( ) www.reuters.com time to read: +1 min

The Johnson & Johnson logo is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 29, 2019. REUTERS/Brendan McDermid/File Photo Acquire Licensing RightsSept 6 (Reuters) - Johnson & Johnson (JNJ.N) said on Wednesday its combination drug helped increase the duration of no progress in a type of non small-cell lung cancer in patients. J&J's therapy was tested in patients in whom the disease progressed even after they were treated with AstraZeneca's Tagrisso. J&J is also testing its combination treatment in a head-to-head study with Tagrisso, and expects data from the trial by the end of this year. If successful, the company expects the therapy to become a first-line treatment for NSCLC patients with the mutation.

Persons: Johnson, Brendan McDermid, AstraZeneca's, Rybrevant, Leroy Leo, Pooja Desai Organizations: New York Stock Exchange, REUTERS, Johnson, Thomson Locations: New York, U.S, Bengaluru

☆ UBS upgrades Big Pharma stock after shares drop on poor drug results
▼ + stars: | 2023-07-13 | by ( Ganesh Rao | ) www.cnbc.com time to read: +3 min

UBS upgraded AstraZeneca 's stock to a "buy" rating despite the drugmaker's trial of a lung cancer medication recently delivering poor results. The investment bank said the subsequent drop in the pharma giant's stock price now meant that "investors can come back to the stock for the performance of in-market products." London-listed shares of AstraZeneca dropped by 8% in a single day, the most in years, after releasing the results of the "TropionLung01" trial for drug candidate "Dato-DXd." UBS expects shares of AstraZeneca to rise by 27% to £13 ($16.8) a share over the next 12 months. These include Imfinzi, a drug for bile duct or gallbladder cancer, and Tagrisso, a treatment for non-small cell lung cancer in adults.

Persons: Michael Leuchten, UBS Michael Leuchten AZN Organizations: UBS, AstraZeneca, pharma, DXd, FDA, Johnson Locations: London, Swiss, Tagrisso

☆ AstraZeneca's Tagrisso slashes death risk in certain post-surgery lung cancer patients
▼ + stars: | 2023-06-04 | by ( Natalie Grover | ) www.reuters.com time to read: +2 min

LONDON, June 4 (Reuters) - AstraZeneca's lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of lung cancer who were diagnosed early enough to have their tumour surgically removed, trial data showed. The drug has regulatory approvals across multiple geographies for certain patients with so-called non small cell lung cancer (NSCLC) who have a mutation of the EGFR gene. In the trial, Tagrisso or a placebo was given to patients to assess whether the AstraZeneca therapy could keep their cancer at bay. An estimated 88% of patients treated with Tagrisso were alive at five years compared to 78% on placebo, trial data also showed. AstraZeneca is also expecting to provide details on the impact of combining Tagrisso with chemotherapy in patients with advanced EGFR-mutated lung cancer later this year.

Persons: Tagrisso, Susan Galbraith, Dave Fredrickson, Natalie Grover, Angus MacSwan Organizations: American Society of Clinical Oncology, AstraZeneca, Reuters, Thomson Locations: Swedish, London

LONDON, April 27 (Reuters) - AstraZeneca (AZN.L) on Thursday beat expectations for its first -quarter profit and revenue, helped by sales of its roster of drugs in emerging markets. The London-listed drugmaker, which reports its results in U.S. dollars, reported adjusted profit of $1.92 per share on sales of about $10.9 billion. Excluding sales of its COVID-19 products, sales grew 22% to $3.1 billion in emerging markets on a constant currency basis. AstraZeneca's best-selling cancer drugs — Tagrisso, Imfinzi and Lynparza — generated $1.4 billion, $900 million and $651 million of sales, respectively, in the quarter. Cowen analysts expected the three drugs to bring in about $1.45 billion, $735 million and $700 million respectively, in quarterly sales.

The company also predicted a return to growth in China, one of its key markets, after reporting a second consecutive quarter of growth even as prices remain under pressure. Sales of its best-selling cancer drugs — Tagrisso, Imfinzi and Lynparza — came in just below estimates from Cowen analysts. Sales started to pick up in the second half of 2022 and in the fourth quarter grew by 3% at constant currency rates. Of key interest to investors is the experimental cancer drug, datopotamab deruxtecan, being evaluated in a keenly anticipated late-stage trial involving lung cancer patients. Partner Daiichi Sankyo (4568.T) this month said results of that study have been delayed to the second quarter from the first quarter of 2023.

☆ AstraZeneca Q4 revenue just shy of analyst estimates
▼ + stars: | 2023-02-09 | by ( ) www.reuters.com time to read: +1 min

Companies AstraZeneca PLC FollowLONDON, Feb 9 (Reuters) - AstraZeneca (AZN.L) on Thursday posted fourth-quarter revenue just shy of analyst estimates, with slightly lower-than-expected sales of its best-selling oncology and rare blood disorder drugs. The London-listed drugmaker, which reports its results in U.S. dollars, reported an adjusted profit of 1.38 cents per share on sales of about $11.2 billion. Analysts were expecting $1.34 per share on sales of about $11.3 billion, according to company-compiled consensus estimates. Sales of AstraZeneca's best-selling cancer drugs — Tagrisso, Imfinzi and Lynparza — generated $1.34 billion, $752 million, $689 million in the quarter respectively. Cowen analysts expected the three drugs to bring in about $1.4 billion, $760 million and $695 million respectively.

In 2022, drugmakers raised prices on more than 1,400 drugs according to data published by 46brooklyn, a drug pricing non-profit that is related to 3 Axis. The median drug price increase was 4.9% last year, while the average increase was 6.4%, according to 46brooklyn. Antonio Ciaccia, president of 3 Axis, said that drugmakers have focused on launching their drugs at higher prices because of the attention paid to annual price increases. More drug prices are likely to be announced over the course of January - historically the biggest month for drugmakers to raise prices. Sanofi plans to raise prices on 14 of its drugs or vaccines.

☆ AstraZeneca tops quarterly estimates buoyed by cancer drug sales
▼ + stars: | 2022-11-10 | by ( Natalie Grover | ) www.reuters.com time to read: +1 min

Sales of AstraZeneca's key cancer medicines — Tagrisso and Imfinzi — helped the company's revenue beat, with sales of its broader oncology portfolio rising 24%. Previously, it had forecast a 2022 gain in the "mid-to-high twenties percentage". Novartis in late October said strong U.S. currency was a drag on the value of its quarterly sales generated outside the United States. AstraZeneca on Thursday said its anticipated 2022 revenue growth would be impacted by a currency headwind of a "mid single-digit percentage". Core earnings per share for the year will also be negatively affected by "mid-to-high single-digit percentage," it added.

☆ AstraZeneca lifts 2022 earnings outlook as cancer drugs boost results
▼ + stars: | 2022-11-10 | by ( Natalie Grover | ) www.reuters.com time to read: +4 min

AstraZeneca is seen as a bellwether for the pharmaceutical sector in China, which accounted for about 16% of the company's total revenue last year. Sales in China have been hurt by lower drug prices while COVID lockdown measures have kept some patients from being diagnosed and seeking care. Better-than-expected sales of AstraZeneca's cancer medicines, including Tagrisso, Imfinzi and Enhertu, helped the company's quarterly revenue beat, with sales of its broader oncology portfolio rising 24%. But global sales of the company's COVID therapy, Evusheld, have steadily grown, partially offsetting the rapid decline in COVID vaccine sales. Evusheld continues to demonstrate strong efficacy but there are a couple of variants that are resistant to it, Soriot said.

☆ Вакцина как бизнес. Сколько зарабатывают на них фармкомпании
▼ + stars: | 2021-07-08 | by ( Mld Media Srl | Степанов Георгий | ) noi.md time to read: +5 min

PfizerКомпания Pfizer заявила, что её вакцина принесла $3,5 млрд выручки за первые три месяца 2021 года. Johnson & Johnson и AstraZenecaАмериканская компания Johnson & Johnson и англо-шведская AstraZeneca пообещали продавать свои вакцины на некоммерческой основе во время пандемии. Вакцина AstraZeneca от COVID-19 принесла создателям в первом квартале 2021 года $275 млн выручки. Johnson & Johnson сообщила, что её вакцина за первые три месяца года принесла $100 млн выручки. Kelly Scientific указывает сумму $59 млрд в 2021 году и снижение её до $47 млрд к 2026 году.

Persons: — BioNTech, Pfizer BioNTech, Johnson, Johnson AstraZeneca Johnson, Sinovac, Morningstar, Kelly, —, Альберт Бурла, Алекс Горски, Джошуа Коэн, Джон ЛаМатинна, Карен Андерсен Organizations: Pfizer, BioNTech, Pfizer Fosun Pharma, Pfizer Pfizer, Johnson, AstraZeneca, AstraZeneca COVID, Guardian, Moderna Johnson, Forbes . Forbes, — Pfizer, Спутник, Всемирная организация здравоохранения (ВОЗ), Африканский союз, Альпари, & Locations: vc.ru, COVID, BioNTech Moderna, вакцинахЕС, США, Евросоюз, Бразилия, Чили, Сингапур, Малайзией, Филиппинами, Турция, Индонезия, Китай, Венгрия, Словакия, ЕС, Россия

Search resuls for: "Tagrisso"

11 mentions found